0.00Open0.08Pre Close0 Volume6 Open Interest10.00Strike Price0.00Turnover242.92%IV210.15%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier28DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type0.0976Delta0.0771Gamma40.63Leverage Ratio-0.0068Theta0.0002Rho3.97Eff Leverage0.0016Vega
Perspective Therapeutics Stock Discussion
I don't even trust my mind
losing everybody
they can never take my grind
📊⚡️📊
Perspective Therapeutics to Discuss Data on [212Pb]VMT-α-NET Presented at the 2024 North American Neuroendocrine Tumor Society (NANETS) Multidisciplinary NET Medical Symposium on November 21, 2024
Perspective Therapeutics (NYSE AMERICAN: CATX) announced the upcoming presentation of initial results from their Phase 1/2a trial of [212Pb]VMT-α-NET at the 2024 NANETS Multidisciplinary NET Medical Symposium. The presentation, titled 'Preliminary safety and eff...
Larger Image: tradingview.com...
$Perspective Therapeutics (CATX.US)$
No comment yet